LONDON (AP) — U.K.-based drugmaker GlaxoSmithKline and Germany’s CureVac say they plan to collaborate to develop new vaccines that can target emerging variants of COVID-19. The announcement comes as public health experts around the world raise concerns about mutations in the virus that may make existing vaccines less effective. The companies said in a statement Wednesday that “the increase in emerging variants with the potential to reduce the efficacy of first generation COVID-19 vaccines requires acceleration of efforts to develop vaccines against new variants to keep one step ahead of the pandemic.”
